title: Clearance and biodistribution of liposomally encapsulated nitroxides: a model for targeted delivery of electron paramagnetic resonance imaging probes to tumors.
abstract: Electron paramagnetic resonance (EPR) imaging using nitroxides as molecular probes is potentially a powerful tool for the detection and physiological characterization of micrometastatic lesions. Encapsulating nitroxides in anti-HER2 immunoliposomes at high concentrations to take advantage of the "self-quenching" phenomenon of nitroxides allows generation of robust EPR signals in HER2-overexpressing breast tumor cells with minimal background from indifferent tissues or circulating liposomes. We investigated the in vivo pharmacological properties of nitroxides encapsulated in sterically stabilized liposomes designed for long circulation times. We show that circulation times of nitroxides can be extended from hours to days; this increases the proportion of liposomes in circulation to enhance tumor targeting. Furthermore, nitroxides encapsulated in sterically stabilized anti-HER2 immunoliposomes can be delivered to HER2-overexpressing tumors at micromolar concentrations, which should be imageable by EPR. Lastly, after in vivo administration, liposomally encapsulated nitroxide signal also appears in the liver, spleen, and kidneys. Although these organs are spatially distinct and would not hinder tumor imaging in our model, understanding nitroxide signal retention in these organs is essential for further improvements in EPR imaging contrast between tumors and other tissues. These results lay the foundation to use liposomally delivered nitroxides and EPR imaging to visualize tumor cells in vivo.
authors: Center for Biomedical Engineering and Technology and Center for EPR Imaging In Vivo Physiology, University of Maryland, Baltimore, Maryland 21201, USA.
authors: Scott R
authors: SR
authors: Burks
authors: Eric A
authors: EA
authors: Legenzov
authors: Gerald M
authors: GM
authors: Rosen
authors: Joseph P Y
authors: JP
authors: Kao
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D003497:Cyclic N-Oxides / Q000493:pharmacokinetics*; D003952:Diagnostic Imaging; D016503:Drug Delivery Systems / Q000379:methods*; D004578:Electron Spin Resonance Spectroscopy / Q000379:methods; D005260:Female; D008081:Liposomes / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D015335:Molecular Probes / Q000493:pharmacokinetics*; D011759:Pyrrolidines / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics; D014018:Tissue Distribution; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
chemical_list: D003497:Cyclic N-Oxides; D008081:Liposomes; D015335:Molecular Probes; D011759:Pyrrolidines; D018719:Erb-b2 Receptor Tyrosine Kinases; C488837:3-carboxy-2,2,5,5-tetramethyl-1-pyrrolidinyloxyl